Orchestra BioMed


Orchestra BioMed is a biomedical innovation company that develops late-stage therapeutic device and drug–device combination candidates and advances them through strategic partnerships and licensing with established medical device companies. The company’s pipeline targets procedure-based cardiovascular indications (including implantable cardiac neuromodulation and focal intravascular drug delivery) and also includes minimally invasive surgical device development. Development activities reported by the company include preclinical testing, randomized clinical trials, regulatory interactions, standards engagement, and partnership-enabled commercialization and supply arrangements.

Industries

biotechnology
health-care
medical
medical-device

Nr. of Employees

medium (51-250)

Orchestra BioMed

New Hope, Pennsylvania, United States, North America


Products

Implantable cardiac neuromodulation therapy (AV-interval modulation)

Programmable cardiac neuromodulation therapy implemented via implantable pulse generator platforms to modulate atrioventricular timing and autonomic responses, intended for patients requiring dual-chamber pacemakers as a mechanism to lower systolic blood pressure.

Non-coated angioplasty angio-infusion balloon system for focal sustained-release sirolimus delivery

An angioplasty balloon system that uses a protected, non-coated porous balloon mechanism to deliver a bioabsorbable sustained-release sirolimus formulation to the vessel wall during angioplasty, designed to provide focal therapeutic delivery without a surface coating or permanent implant.

Intracorporeal hands-free adjustable surgical retractor system

A fully adjustable, hands-free intracorporeal surgical retractor designed to optimize visualization, minimize incision size and procedural collisions, and enable surgeon-controlled positioning throughout minimally invasive procedures.


Services

Strategic development partnerships and licensing

Structures and executes development, clinical, regulatory and commercialization collaborations with established medical device companies to advance device and drug–device candidates, including partner-managed manufacturing and commercialization transitions.

Late-stage clinical program management and evidence generation

Operational leadership for multicenter randomized and registry trials, core-lab endpoint adjudication, statistical analysis, regulatory submission support and preparation of peer-reviewed publications.

Expertise Areas

  • Clinical trial management and endpoint adjudication
  • Bioelectronic neuromodulation therapy development for hypertension
  • Drug–device combination product development and formulation
  • Interventional vascular device development and engineering
  • Show More (4)

Key Technologies

  • Programmable cardiac pacing algorithms for atrioventricular interval modulation
  • Implantable pulse generator integration with dual-chamber pacing leads
  • Porous/microporous angioplasty balloon-mediated focal drug infusion
  • Nanoparticle-encapsulated bioabsorbable sustained-release drug formulations
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.